ENTRY       D12142            Mixture   Drug
NAME        Casirivimab and imdevimab;
            Casirivimab (genetical recombination) and imdevimab (genetical recombination);
            Regen-cov (TN);
            Ronapreve (TN)
COMPONENT   Casirivimab [DR:D11938], Imdevimab [DR:D11939]
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
REMARK      Therapeutic category: 6250
            ATC code: J06BD07
            Product: D12142<JP>
EFFICACY    Antiviral
  TYPE      Monoclonal antibody, combination
TARGET      SARS-CoV-2 spike glycoprotein [KO:K24152]
  PATHWAY   ko03230(K24152)  Viral genome structure
            ko05171(K24152)  Coronavirus disease - COVID-19
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J06 IMMUNE SERA AND IMMUNOGLOBULINS
               J06B IMMUNOGLOBULINS
                J06BD Antiviral monoclonal antibodies
                 J06BD07 Casirivimab and imdevimab
                  D12142  Casirivimab and imdevimab &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D12142  Casirivimab and imdevimab
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12142  Casirivimab and imdevimab
            Drug classes [BR:br08332]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12142  Casirivimab and imdevimab
            Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               Coronavirus spike protein
                D12142  Casirivimab and imdevimab &lt;JP&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12142
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12142
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12142
///
